Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Jörg Distler, MD
University Hospital Duesseldorf and HHU
Duesseldorf, Germany
Disclosure(s): 4D Science: Royalties (Ongoing); AbbVie: Consultant (Ongoing); Anamar: Consultant (Ongoing), Grant/Research Support (Ongoing); Argenx: Grant/Research Support (Ongoing); ARXX: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Boehringer Ingelheim: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Cantargia: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); CSL Behring: Grant/Research Support (Ongoing); FibroCure: Ownership Interest (Ongoing); Genentech/Roche: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Lassen: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); RedX: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
Carol Feghali-Bostwick, PhD
Medical University of South Carolina
Charleston, SC, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Michael Whitfield, PhD
Geisel School of Medicine
Lebanon, NH, United States
Disclosure(s): Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Celdara Medical: Consultant (Ongoing), Grant/Research Support (Ongoing), Scientific Founder (Ongoing)
Therapeutics, which have shown promise in traditional pre-clinical scleroderma systems, including 2D fibroblast culture and mouse models such as bleomycin-induced fibrosis, have frequently failed to prove efficacious in human disease. This may be due both to technical limitations in these systems, as well as the heterogeneity of systemic sclerosis. This session will discuss how best to utilize pre-clinical models and emerging techniques, which can allow for systems to better recapitulate human disease conditions, including differences across patients
Speaker: Carol Feghali-Bostwick, PhD – Medical University of South Carolina
Speaker: Jörg Distler, MD – University Hospital Duesseldorf and HHU
Speaker: Michael Whitfield, PhD – Geisel School of Medicine